ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 3, 2009--
InSite Vision Incorporated (OTCBB:INSV) announced today that it will
release financial results for the third quarter 2009 on Wednesday,
November 11, 2009.
Company management will host a conference call beginning at 4:30 PM
EST/1:30 PM PST to discuss results and review recent accomplishments.
Investors can submit questions prior to the conference call via the
company's website at www.insitevision.com
through the "Information Request" tab on the Investor Relations page.
Analysts and investors can listen to the conference call by dialing
(877) 407-0778 for domestic callers and (201) 689-8565 for international
callers. A telephone replay will be available following the conclusion
of the call by dialing (877) 660-6853 for domestic callers and (201)
612-7415 for international callers. All callers will need to enter the
account number 286 and conference ID 336735.
The live conference call will also be webcast and available on the
Investor Relations page of the company's website at www.insitevision.com.
A press release detailing third quarter 2009 financial results will also
be posted to the company's website and furnished to the Securities and
Exchange Commission on a Form 8-K prior to the conference call described
About InSite Vision
InSite Vision is committed to advancing new and superior ophthalmologic
products for unmet eye care needs. InSite Vision is recognized for the
discovery and development of novel ocular pharmaceutical products based
on its DuraSite® bioadhesive polymer core technology, an innovative
platform that extends the duration of drug delivery on the eye’s
surface, thereby reducing frequency of treatment and improving the
efficacy of topically delivered drugs. The DuraSite platform is
currently leveraged in two commercial products for the treatment of
bacterial eye infections, AzaSite® (azithromycin ophthalmic solution) 1%
and Besivance™ (besifloxacin ophthalmic suspension) 0.6%. AzaSite is
approved in the United States and Canada and currently marketed by
InSite Vision’s partner, Inspire Pharmaceuticals in the United States.
InSite Vision has formed multiple strategic licensing and distribution
agreements with qualified partners to market AzaSite in select countries
in Asia and South America upon regulatory approval in those regions.
Besivance was approved by the U.S. Food and Drug Administration in the
second quarter 2009 and is being marketed by Bausch & Lomb and Pfizer
InSite Vision’s ophthalmic product development pipeline also includes
ISV-502 and additional product candidates leveraging the company’s core
technologies. For further information on InSite Vision, please visit www.insitevision.com.
Source: InSite Vision Incorporated
Louis Drapeau, 510-747-1220
Ellen Rose, 650-387-8746 (Media inquiries)